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Summary
Background Uptake of self-testing and self-management of oral anticoagulation has remained inconsistent, despite 
good evidence of their eﬀ ectiveness. To clarify the value of self-monitoring of oral anticoagulation, we did a meta-
analysis of individual patient data addressing several important gaps in the evidence, including an estimate of the 
eﬀ ect on time to death, ﬁ rst major haemorrhage, and thromboembolism.
Methods We searched Ovid versions of Embase (1980–2009) and Medline (1966–2009), limiting searches to randomised 
trials with a maximally sensitive strategy. We approached all authors of included trials and requested individual 
patient data: primary outcomes were time to death, ﬁ rst major haemorrhage, and ﬁ rst thromboembolic event. We did 
prespeciﬁ ed subgroup analyses according to age, type of control-group care (anticoagulation-clinic care vs primary 
care), self-testing alone versus self-management, and sex. We analysed patients with mechanical heart valves or atrial 
ﬁ brillation separately. We used a random-eﬀ ect model method to calculate pooled hazard ratios and did tests for 
interaction and heterogeneity, and calculated a time-speciﬁ c number needed to treat.
Findings Of 1357 abstracts, we included 11 trials with data for 6417 participants and 12 800 person-years of follow-up. 
We reported a signiﬁ cant reduction in thromboembolic events in the self-monitoring group (hazard ratio 0·51; 95% CI 
0·31–0·85) but not for major haemorrhagic events (0·88, 0·74–1·06) or death (0·82, 0·62–1·09). Participants younger 
than 55 years showed a striking reduction in thrombotic events (hazard ratio 0·33, 95% CI 0·17–0·66), as did 
participants with mechanical heart valve (0·52, 0·35–0·77). Analysis of major outcomes in the very elderly 
(age ≥85 years, n=99) showed no signiﬁ cant adverse eﬀ ects of the intervention for all outcomes.
Interpretation Our analysis showed that self-monitoring and self-management of oral anticoagulation is a safe option 
for suitable patients of all ages. Patients should also be oﬀ ered the option to self-manage their disease with suitable 
health-care support as back-up.
Funding UK National Institute for Health Research (NIHR) Technology Assessment Programme, UK NIHR National 
School for Primary Care Research.
Introduction
Oral anticoagulation with vitamin K antagonists sub-
stantially reduces the incidence of thromboembolic 
events.1–4 Although the number of patients receiving oral 
anticoagulants has consistently increased, uptake is 
limited by requirements to maintain the international 
normalised ratio (INR) within a narrow target range, 
which includes frequent testing and appropriate dose 
adjustments. Beneﬁ ts shown in clinical trials might not 
translate into routine practice: namely the risk of major 
bleeding could be high in speciﬁ c populations of patients, 
especially in the elderly.2
Introduction of reliable and analytically accurate point-
of-care devices allows self-testing by the patient in the 
home setting.1,2 Patients can have their test result 
managed by their health-care provider (self-testing) or 
they can interpret their INR result, and adjust their own 
dose of anticoagulant accordingly (self-management).
Previous systematic reviews4–6 showed that self-
monitoring is a safe intervention, which gives rise to 
signiﬁ cant reduction in thromboembolic events, while 
reducing the risk of death. Additionally, patients spend 
more time in the therapeutic range of INR than they 
would without self-monitoring. However, previous 
conclusions were limited by methodological problems 
and inadequate reporting of important outcome data over 
time.4–6 Also important subgroup analyses, stratiﬁ ed by 
age and indication for anticoagulation therapy, have not 
been possible.
Uptake of self-testing and self-management has 
remained inconsistent in and between countries, despite 
good evidence of their eﬀ ectiveness and guidelines 
encour aging patients to discuss this option with clinical 
staﬀ .1,7,8 To clarify further the value of self-monitoring of 
oral anticoagulation we did a meta-analysis of individual 
patient data, which updated our previous systematic 
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reviews and enabled more detailed analysis than 
previously. Speciﬁ cally, we aimed to address several 
important gaps in the evidence, including obtaining an 
estimate of the eﬀ ect of self-monitoring on time to 
death, ﬁ rst major haemorrhage, and ﬁ rst thrombo-
embolic event. We also aimed to investigate eﬀ ects in 
important subgroups such as the elderly and those with 
speciﬁ c disease indications for anticoagulation such as 
atrial ﬁ brillation or mechanical heart valve.
Methods
Search strategy and study selection
The protocol methods have been previously pub-
lished.9 We used the same search strategy as for 
previous reviews.4–6 We searched Ovid versions of Embase 
(1980–2009) and Medline (1966–2009), limiting searches 
to randomised trials with a maximally sensitive strategy.10 
A list of search terms is shown in webappendix pp 1–3. 
We modiﬁ ed these searches for the Cochrane Central 
Register of Controlled Trials, the Cochrane Library, 
issue 2, 2009, and Cinahl (1982–2009). We also searched 
for trials that are still underway or unpublished (eg, UK 
National Research Register and Trials Central), and hand-
searched reference lists of retrieved papers.
Trial eligibility and quality assessment
We included randomised trials that compared the 
eﬀ ects of self-monitoring (self-testing) or self-manage-
ment (self-testing and self-dosage) of anti co agulation 
with control and dosage by personal physician, 
anticoagulation management clinics, or managed 
services, or reported the clinical outcomes of thrombo-
embolic events and major bleeding episodes. We 
included studies of adults on anticoagulant therapy 
irrespective of the indication for treatment, with no 
language restrictions.
As in our previous systematic review,5 we assessed the 
quality of studies by the presence of randomisation, 
allocation concealment, masked outcome assessments, 
intention-to-treat analysis, and attrition rates. Two 
reviewers (CH and AW) independently assessed the 
articles for inclusion, and disagreements were resolved 
by discussion.
Data extraction
We approached all authors whose trials met the inclusion 
criteria and requested the following data for individual 
patients: date of randomisation, age, indication for 
treatment, type of care, demographic and psychosocial 
characteristics at randomisation including quality-of-life 
measures, treatment allocation, time to death, time to 
ﬁ rst major haemorrhage, time to ﬁ rst thromboembolic 
event, and INR measurements.
Data validation
We kept original data on a secure server with a back-up 
copy according to a prespeciﬁ ed data-security-agree ment 
policy. Two researchers (CB and AF) cross-checked trial 
details, summary measures, and major outcomes were 
cross-checked with prespeciﬁ ed outcome deﬁ nitions 
against published articles. Any incon sistencies were 
discussed with the original trialist and corrections were 
made when appropriate. Requirements for authorship 
were those of the International Committee of Medical 
Journal Editors and a representative of each trial was 
invited to an investigators’ meeting before publication to 
discuss analysis and results.
Statistical analysis
Primary outcomes were time to death, ﬁ rst major 
haemorrhage, and ﬁ rst thromboembolic events. Major 
haemorrhages included: 1) bleeding that was fatal, 2) 
symptomatic bleeding in a critical area or organ such as 
intracranial, intraspinal, intraocular, retroperitoneal, 
intra-articular or pericardial, or intramuscular with 
compartment syndrome; and 3) bleeding causing a fall 
in haemoglobin concentrations of 20 g/L (1·24 mmol/L) 
or more, or leading to transfusion of two units of packed 
red-blood cells. Thromboembolic events were stroke, 
arterial embolism, symptomatic deep-vein thrombosis, 
or pulmonary embolism.11
One secondary outcome was time in therapeutic 
range. For individual data, time-to-event outcomes were 
summarised as log (hazard ratio), and time in range as 
mean (SD). We used the survival-curve and hazard-ratio 
programme SCHARP (version 4) for meta-analysis of 
individual patient data. SCHARP is an SAS application 
for meta-analysis of individual patient data with a point-
and-click interface that produces publication-quality 
graphs and appropriate summary statistics for time-to-
event data.12
We used SPSS (version 17) for analysis of baseline 
characteristics. We did prespeciﬁ ed subgroup analyses for 
the primary outcomes with the following age bands (<55, 
55–64, 65–74, and ≥75 years), the type of control-group 
care, type of self-monitoring, and sex. We also analysed 
patients who had mechanical heart valves, atrial ﬁ brillation, 
and other indications separately, stratifying them by age 
(<65 years and ≥65 years).
Because the components of the interventions diﬀ er 
somewhat (eg, in terms of their training and education) 
and in assuming a diﬀ erent underlying eﬀ ect for each 
trial intervention, a random eﬀ ects model was used to 
calculate pooled hazard ratios. Random eﬀ ects generally 
lead to wider CIs than the ﬁ xed eﬀ ects; however, when 
no heterogeneity is present the results of the ﬁ xed and 
random eﬀ ects are equivalent. Time-to-event outcomes 
were analysed with hazard ratios, which take into 
account the number and timing of events, and the time 
until last follow-up for each patient not experiencing an 
event. We used a two-step process for meta-analysis: a 
hazard ratio was estimated for each trial and then hazard 
ratios were pooled in a meta-analysis. The log-rank 
observed-minus-expected statistic and its variance were 
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calculated for each trial.13 We examined heterogeneity 
with the I² statistics.14,15 We also did tests for interaction 
between subgroups of patients, partitioning the total 
heterogeneity across all trials into within-group and 
between-group heterogeneity (the test for interaction). 
We calculated a time-speciﬁ c number needed to treat at 
various timepoints with the method outlined by Altman 
and Andersen,16 
where at a speciﬁ ed timepoint (t), the survival probability 
in the control group is Sc(t), then the survival probability 
in the active group is Sc(t)h, where h is the hazard ratio 
comparing the treatment groups. The number needed 
to treat represents the number of patients treated in the 
intervention group for one less primary outcome event 
over the time stipulated. For subgroups, we calculated 
the average eﬀ ect over 5 years based on the control 
event rate. All analyses were on an intention to treat 
basis. We deviated from our original protocol in that we 
did not present data on psychological factors, which we 
hope to report elsewhere.
Suﬃ  cient data from eight trials17–24 were available for us 
to calculate the mean time in therapeutic range at 
timepoints of 7 days, 30 days, 90 days, 6 months, and 
1 year by the method of linear interpolation set out by 
Rosendaal and colleagues.25 We assessed publication bias 
by constructing a funnel plot of precision (SE of the log 
hazard ratio) against hazard ratio for the endpoints of 
major haemorrhage and thromboembolic events,6 and 
did Begg’s and Egger’s tests.15
1357 potential records identified
1313 excluded
45 full text articles reviewed
 5 systematic reviews
23 excluded
8 duplicates
15 not randomised trials 
21 randomised trials identified
(7598 participants)
10 excluded
10 did not have data available
(1181 participants)
11 trials included
(6417 participants)
Figure 1: Flow chart of studies
Country Dates of 
recruitment
Year of 
publication 
of primary 
results
Study 
duration 
(months)
Age range, 
years (mean)
Total 
number of 
patients
Female Atrial 
ﬁ brillation
Mechanical 
valve
Other Self 
manage-
ment
Type of control 
group care
Beyth et al36* USA 1992–95 2000 6 65–94 (74·7) 325 (5%) 184 (57%) 54 (17%) 36 (11%) 235 (72%) No Primary Care
Cromheecke 
et al17†
Holland 1998 2000 3 22–71 (42·3) 49 (1%) 21 (43%) 11 (22%) 23 (47%) 15 (31%) Yes Anticoagulation 
clinic
Koertke et al18† Germany 1994–97 2001 24 17–77 (59·7) 930 (14%) 293 (32%) ·· 930 (100%) ·· Yes Primary care
Sunderji et al37‡ Canada 1998–2002 2004 20 20–85 (60·0) 139 (2%) 41 (29%) 47 (34%) 82 (59%) 10 (7%) Yes Primary care
Menéndez-
Jándula et al19†
Spain 2001–02 2005 12 19–90 (63·5) 737 (11%) 347 (47%) 296 (40%) 285 (39%) 154 (21%)§ Yes Anticoagulation 
clinic
Völler et al38† Germany 1999–2001 2005 19¶ 36–85 (64·4) 202 (3%) 53 (26%) 202 (100%) ·· ·· Yes Primary care
Fitzmaurice 
et al20†
UK 2001–02 2005 12 18–87 (65·1) 617 (10%) 217 (35%) 343 (56%) 97 (16%) 177 (29%) Yes Both
Christensen 
et al21†
Denmark 2002–03 2006 6 21–78 (50·7) 100 (2%) 33 (33%) 24 (24%) 35 (35%) 41 (41%) Yes Both
Siebenhofer 
et al23†
Austria 2002–05 2007 36 60–89 (68·8) 195 (3%) 81 (42%) 89 (46%) 32 (16%) 74 (38%) Yes Both
Matchar et al22‡ USA 2003–06 2010 36 23–90 (67·0) 2922 (46%) 51 (2%) 2236 (77%)|| 684 (23%) 2 (<1%) No Anticoagulation 
clinic
Kaatz et al24† USA 1998–99 2001 12 30–87 (64·1) 201 (3%) 84 (42%) 86 (43%) 39 (19%) 76 (38%) No Anticoagulation 
clinic
Totals ·· 1992–2006 2000–10 ·· 17–94 (65·0) 6417 1405 (22%) 3388 (53%) 2243 (35·0%) 784 (12%) ·· ··
Data are range (mean) or number (%). *Coumatrack monitor.†Coaguchek system. ‡Pro time microcoagulation system.§Two patients were unclassiﬁ ed for indication. ¶Study stopped early. ||2236 with no 
mechanical heart valve, 2422 had atrial ﬁ brillation, mechanical heart valve, or both.
Table 1: Characteristics of studies
1
(Sc[t]h–Sc[t])
Number needed to treat =
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Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for 
publication. 
Results
Of 1357 abstracts, we identiﬁ ed 21 trials (20 published, 
one unpublished) that met the eligibility criteria 
(ﬁ gure 1). We were unable to obtain adequate data from 
ten trials.26–35 These trials were small, ranging from 
50–320 participants (total 1181 participants). Of 
21 original trials, including 7598 participants, we present 
results for 6417 (84%) participants.
Table 1 shows 11 included trials: three in the USA,22,24,36 
two in Germany,18,38 and one each from Austria and 
Germany,23 Canada,37 Denmark,21 Nether lands,17 Spain19 
and the UK.20 Participant recruitment into the trials 
occurred from 1992 to 2006, and trials were published 
between 2000 and 2010. The Coaguchek (Roche 
Diagnostics, Basel, Switzerland), Pro time micro-
coagulation (ITC Nexus Dx, Edison, NJ USA), and the 
Coumatrak monitor (Du Pont Pharmaceuticals, 
Wilmington, DE, USA) systems were used (table 1). For 
all trials, we veriﬁ ed clear methods for randomisation, 
allocation concealment, and intention-to-treat analyses. 
For publication bias, we saw no funnel-plot asymmetry 
and no bias with Begg’s test: p=0·35 for thromboembolic 
events and p=1·00 for major haemorrhage; 
corresponding results of Egger’s test were p=0·05 for 
thromboembolic events and p=0·92 for major 
haemorrhage. 3266 (51%) participants were randomly 
allocated to self-monitoring and 3151 to conventional 
care. Participants in the intervention group were on 
average 1·7 years (64·2 [SD 11·7] years vs 65·9 [SD 10·5] 
years; p<0·0001) younger than those in the control 
groups. A wide range of ages was included: from 17 to 
94 years of age, with 99 participants aged 85 years or 
older. 12 800 person years of follow-up were obtained 
(mean 1·99 years [SD 1·22]), with a maximum follow-up 
of 1888 days (5·17 years).
Over a third of participants had a mechanical heart 
valve insertion; one trial18 included only participants 
with this indication. Over half of participants had atrial 
ﬁ brillation; one trial38 included only participants with 
this indication. For other disorders, over 10% of 
participants from nine trials17,19–24,36,37 were included. In 
eight trials,17–21,23,37,38 just under half (46%) of those in the 
intervention group used self-management and in three 
trials,22,24,36 just over half (54%) used self-testing only with 
dose adjustments undertaken by their regular clinician 
(table 1).
In four trials18,36–38 including a quarter of participants, 
primary care was used as the control and in another four 
trials17,19,22,24 including more than half (61%) of participants, 
specialist anticoagulation clinics were used (table 1). 
In the three remaining trials,20,21,23 the control included 
either primary care or specialist clinics (table 1).
A signiﬁ cant reduction in thromboembolic events was 
seen in the self-monitoring group (hazard ratio 0·51, 
95% CI 0·31–0·85; p=0·010; I²=52·6%; ﬁ gure 2). 
At 1 year, the number needed to treat to prevent one 
thromboembolic event was 78 (95% CI 55–253), and by 
5 years it was 27 (19–87; table 2). Individual study hazard 
ratios are shown in webappendix p 4. No signiﬁ cant 
reduction in major haemorrhagic events (hazard ratio 
0·88, 95% CI, 0·74–1·06; p=0·18, I²=0) or in deaths 
(0·82, 0·62–1·09; p=0·18; I²= 37·0) were apparent with 
self-monitoring (ﬁ gure 2).
Number at risk
Control
Self-monitoring
0
3151 (84)
3266 (43)
1
2137 (39)
2232 (38)
2
1214 (17)
1299 (19)
3
771 (7)
846 (12)
4
275 (4)
317 (2)
5
0
0
Time (years)
Hazard ratio 0·51 (95% CI 0·31–0·85; p=0·01)
Hazard ratio 0·88 (95% CI 0·74–1·06; p=0·18)
Hazard ratio 0·82 (95% CI 0·62–1·09; p=0·18)
0
10
20
30
40
50
Pr
ob
ab
ili
ty
 o
f a
n 
ev
en
t (
%
)
Control
Self-monitoring
Number at risk
Control
Self-monitoring
0
3151 (131)
3266 (106)
1
2109 (56)
2189 (64)
2
1189 (30)
1273 (31)
3
742 (24)
820 (21)
4
251 (2)
296 (1)
5
0
0
Time (years)
0
10
20
30
40
50
Pr
ob
ab
ili
ty
 o
f a
n 
ev
en
t (
%
)
Number at risk
Control
Self-monitoring
0
3151 (130)
3266 (96)
1
2197 (67)
2271 (76)
2
1264 (48)
1346 (46)
3
816 (19)
884 (24)
4
296 (5)
334 (4)
5
0
0
Time (years)
0
10
20
30
40
50
Pr
ob
ab
ili
ty
 o
f a
n 
ev
en
t (
%
)
A
B
C
Figure 2: Hazard ratios for major outcomes
Hazard ratios for thrombotic events (152 events in the control group, 114 in the self-monitoring group; A), 
haemorrhagic events (244 in the control group, 230 in the self-monitoring group; B), and death (274 in the 
control group, 247 in the self-monitoring group; C).
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In prespeciﬁ ed subgroups the rate of thromboembolic 
events in men was signiﬁ cantly reduced in the self-
monitoring group (ﬁ gure 3; p=0·010; I²=61·3) whereas 
in women it was not (ﬁ gure 3; p=0·46; I²=26·6;). 
However, the ratio of male to female participants was 
four to one (5012 men vs 1405 women) and the interaction 
test showed that these two subgroups did not diﬀ er 
signiﬁ cantly (χ² 0·01; p=0·94). Participants younger than 
55 years of age who self-monitored had a striking 
reduction in thromboembolic events (ﬁ gure 3; p=0·002; 
I²=0), whereas in other age groups non-signiﬁ cant eﬀ ects 
were shown. In participants younger than 55 years, this 
result corresponded to a number needed to treat 
of 21 (95% CI 17–42) to prevent one thromboembolic 
event at 1 year. Non-signiﬁ cant improvement in major 
outcomes was seen in the self-monitoring group with 
younger age (χ² 7·75; p=0·052).
In terms of indication, participants with a mechanical 
heart valve who self-monitored had signiﬁ cant reductions 
in thromboembolic events (ﬁ gure 3; p=0·001; I²=0). 
At 1 year the number needed to treat to prevent one event 
was 55 (95% CI 41–116) and by 5 years it was 24 (18–50). 
Eﬀ ects for both atrial ﬁ brillation (ﬁ gure 3; p=0·35; 
I²=40·9) and other indications (ﬁ gure 3; p=0·12; I²=0) 
were not signiﬁ cant. An interaction test (χ² 6·88, 
p=0·032) between indications was signiﬁ cant. Partici-
pants who self-managed oral anticoagulation also had 
signiﬁ cantly fewer thromboembolic events (ﬁ gure 4; 
p<0·001; I²=0), whereas participants self-testing alone 
did not (ﬁ gure 4; p=0·51; I²=50·3). The interaction test 
between self-testing and self-management for this 
diﬀ erence was signiﬁ cant (χ² 9·81, p=0·002). For 
participants self-managing, the number needed to 
treat to prevent one thromboembolic event was 39 
(95% CI 31–65). For major haemorrhage and death, we 
detected no signiﬁ cant eﬀ ects or interactions by age, sex, 
indication, or type of monitoring (ﬁ gure 3).
Number needed 
to treat (95% CI)
Number of patients 
still at risk
All participants (N=6417)
Thrombosis
Year 1 78 (55 to 253) 4369
Year 2 47 (33 to 154) 2513
Year 3 36 (26 to 119) 1617
Year 4 32 (23 to 104) 592
Year 5 27 (19 to 87) ··
Major Haemorrhage
Year 1 205 (94 to ∞) 4598
Year 2 123 (59 to ∞) 2462
Year 3 96 (44 to ∞) 1564
Year 4 74 (34 to ∞) 547
Year 5 70 (32 to ∞) ··
Death
Year 1 137 (65 to ∞) 4468
Year 2 82 (39 to ∞) 2610
Year 3 55 (26 to ∞) 1700
Year 4 47 (22 to ∞) 630
Year 5 42 (20 to ∞) ··
Mechanical valve only (n=2243)
Thrombosis
Year 1 55 (41 to 116) 1721
Year 2 37 ( 28 to 78) 589
Year 3 33 ( 25 to 70 ) 419
Year 4 31 ( 23 to 65) 186
Year 5 24 (18 to 50) 0
Major haemorrhage
Year 1 127 (66 to ∞) 1699
Year 2 65 (34 to ∞) 565
Year 3 43 (22 to ∞) 386
Year 4 31 (16 to ∞) 160
Year 5 29 (15 to ∞) ··
Death  
Year 1 156 (67 to ∞) 1763
Year 2 65 (34 to ∞) 618
Year 3 43 (23 to ∞) 442
Year 4 31 (16 to ∞) 202
Year 5 29 (15 to ∞) ··
Atrial ﬁ brillation only (n=3388)
Thrombosis
Year 1 185 (85 to ∞) 2386
Year 2 91 (42 to ∞) 1860
Year 3 65 (30 to ∞) 1163
Year 4 54 ( 25 to ∞) 393
Year 5 49 (23 to ∞) ··
Major haemorrhage
Year 1 675 (79 to ∞)* 2344
Year 2 453 (53 to ∞)* 1824
Year 3 342 (40 to ∞)* 1134
Year 4 268 (32 to ∞)* 373
Year 5 255 (30 to ∞)* ··
(Continues in next column)
Number needed to 
treat (95% CI)
Number of patients 
still at risk
(Continued from previous column)
Death
Year 1 101 (50 to ∞) 2428
Year 2 56 (28 to ∞) 1921
Year 3 37 (18 to ∞) 1216
Year 4 30 (15 to ∞) 413
Year 5 26 (13 to ∞) ··
The number needed to treat is estimated as: 
*Number needed to harm.
Table 2: Number needed to treat at various timepoints for all 
self-monitoring participants with a mechanical valve and atrial 
ﬁ brillation compared with standard care
1
(Sc[t]h–Sc[t])
Number needed to treat =
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Self-monitoring Control O–E Variance Hazard ratio (random) HR (95% CI) Interaction test
Sex
Male
Female
Age (years)
<55
55–64
65–74
≥75
Indication
Mechanical valve
Atrial ﬁbrillation
Other
Self-monitoring
Self-testing only
Self-management
Type of control group care
Anticoagulation clinic
Primary care
Total
 96/2453
 18/539
 11/496
 33/895
 44/1038
 26/488
 36/1132
 70/1629
 8/261
 89/1566
 25/1487
 92/1959
 16/995
 114/3053
–17·57
–3·28
–9·17
–2·17
–9·88
1·02
–16·22
–0·06
–3·87
–2·83
–18·52
–11·46
–6·34
54·73
11·13
8·37
16·59
27·06
13·03
24·58
34·58
6·30
44·44
21·57
50·83
10·44
 124/2323
 28/555
 25/338
 34/798
 66/1117
 27/538
 63/1040
 69/1623
 20/237
 89/1557
 63/1382
 112/1950
 27/893
 152/2939
A
Sex
Male
Female
Age (years)
<55
55–64
65–74
≥75
Indication
Mechanical valve
Atrial ﬁbrillation
Other
Self-monitoring
Self-testing only
Self-management
Type of control group care
Anticoagulation clinic
Primary care
Total
201/2542
29/618
25/500
66/812
78/1110
61/583
78/1111
126/1676
26/260
190/1729
40/1487
182/1959
42/1158
230/3216
–9·86
–5·15
–2·71
6·67
–11·66
–4·48
–10·11
2·35
–6·90
–11·41
–3·27
–8·27
–4·02
99·83
17·56
11·79
27·16
43·86
33·49
41·66
60·60
13·87
96·81
20·89
91·58
21·89
 201/2403
 43/639
 24/340
 44/699
 101/1185
 75/640
 
 91/1015
 119/1677
 34/281
 
 200/1719
 44/1382
 
 187/1950
 46/1055
 
 244/3101
B
204/2440
43/618
14/495
46/874
98/1034
89/583
64/1101
138/1555
45/334
195/1729
52/1342
159/1934
72/988
247/3071
–17·06
–2·81
–3·56
–2·84
–15·44
4·74
–9·66
–14·32
3·71
–8·94
–12·04
–10·62
–13·02
105·04
24·11
6·61
22·82
55·65
42·91
34·54
72·67
21·53
98·73
31·05
82·83
40·20
 219/2297
 55/639
 15/353
 46/781
 129/1112
 84/640
 75/1002
 156/1549
 43/349
 201/1719
 73/1237
 173/1926
 90/884
 274/2956
Sex
Male
Female
Age (years)
<55
55–64
65–74
≥75
Indication
Mechanical valve
Atrial ﬁbrillation
Other
Self-monitoring
Self-testing only
Self-management
Type of control group care
Anticoagulation clinic
Primary care
Total
C
0·40 (0·20–0·80)
0·76 (0·36–1·58)
0·33 (0·17–0·66)
0·80 (0·45–1·42)
0·69 (0·48–1·01)
0·96 (0·41–2·26)
0·52 (0·35–0·77)
0·67 (0·28–1·57)
0·54 (0·25–1·18)
0·74 (0·30–1·82)
0·42 (0·28–0·65)
0·44 (0·17–1·14)
0·55 (0·28–1·08)
0·51 (0·31–0·85)
0·91 (0·74–1·10)
0·75 (0·47–1·19)
0·79 (0·45–1·41)
1·28 (0·88–1·86)
0·77 (0·57–1·03)
0·87 (0·62–1·23)
0·78 (0·58–1·06)
1·04 (0·81–1·34)
0·61 (0·36–1·03)
0·84 (0·64–1·12)
0·86 (0·56–1·31)
0·91 (0·74–1·12)
0·83 (0·50–1·36)
0·88 (0·74–1·06)
0·85 (0·70–1·03)
0·89 (0·44–1·81)
0·58 (0·22–1·57)
0·72 (0·36–1·41)
0·76 (0·58–0·99)
1·12 (0·83–1·51)
0·80 (0·42–1·52)
0·72 (0·43–1·20)
1·19 (0·78–1·81)
0·91 (0·75–1·11)
0·75 (0·42–1·33)
0·82 (0·52–1·28)
0·72 (0·44–1·18)
0·82 (0·62–1·09)
p=0·94
p=0·052
p=0·032
p=0·002
p=0·34
p=0·45
p=0·20
p=0·13
p=0·87
p=0·60
p=0·84
p=0·19
p=0·23
p=0·15
p=0·20
0·1 0·2 100·5 2 51
Favours self-monitoring Favours control 
Figure 3: Major outcomes by sex, age, indication, type of monitoring and control group care
Thrombosis (A), major haemorrhage (B), and death (C). O–E=observed minus expected.
Articles
328 www.thelancet.com   Vol 379   January 28, 2012
Self-management
Christensen21
Cromheecke17
Fitzmaurice20
Koertke18
Menéndez-Jándula19
Siebenhofer23
Sunderji37
Völler38
Subtotal
Self-testing only
Kaatz24
Matchar22
Beyth36
Subtotal
Total
Self-management
Christensen21
Cromheecke17
Fitzmaurice20
Koertke18
Menéndez-Jándula19
Siebenhofer23
Sunderji37
Völler38
Subtotal
Self-testing only
Kaatz24
Matchar22
Beyth36
Subtotal
Total
Self-management
Christensen21
Cromheecke17
Fitzmaurice20
Koertke18
Menéndez-Jándula19
Siebenhofer23
Sunderji37
VÖller38
Subtotal
Self-testing only
Kaatz24
Matchar22
Beyth36
Subtotal
Total
0/50
0/25
4/337
12/488
3/368
6/99
0/69
0/101
25/1487
2/101
87/1465
0/163
89/1566
114/3053
0/50
0/25
5/337
25/488
3/368
6/99
0/69
1/101
40/1487
32/101
147/1465
11/163
190/1729
230/3216
1/50
0/25
13/337
18/488
5/368
15/99
0/69
0/101
52/1342
2/101
152/1465
41/163
195/1729
247/3071
0/50
2/24
3/280
21/442
21/369
13/96
2/70
1/101
63/1382
6/100
83/1457
0/162
89/1557
152/2939
0/50
1/24
4/280
20/442
7/269
11/96
1/70
0/101
44/1382
36/100
143/1457
21/162
200/1719
244/3101
0/50
0/24
11/280
36/442
15/369
11/96
0/70
0/101
73/1237
1/100
157/1457
43/162
201/1719
274/2956
0·13 (0·01–2·03)
1·63 (0·33–8·12)
0·50 (0·25–1·00)
0·27 (0·12–0·62)
0·47 (0·19–1·16)
0·14 (0·01–2·18)
0·17 (0·00–8·75)
0·42 (0·28–0·65)
0·35 (0·09–1·41)
0·98 (0·73–1·33)
0·74 (0·30–1·82)
0·51 (0·31–0·85)
0·13 (0·00–6·55)
1·03 (0·28–3·84)
1·10 (0·61–1·98)
0·54 (0·16–1·89)
0·57 (0·22–1·47)
0·14 (0·00–6·92)
7·01 (0·14–354·01)
0·86(0·56–1·31)
0·81 (0·50–1·32)
0·96 (0·76–1·21)
0·52(0·26–1·05)
0·84 (0·64–1·12)
0·88 (0·74–1·06)
7·07 (0·14–356·58)
0·98 (0·44–2·19)
0·45 (0·26–0·77)
0·46 (0·19–1·12)
1·40 (0·65–3·02)
0·75 (0·42–1·33)
1·93 (0·20–18·60)
0·91 (0·73–1·14)
0·90 (0·59–1·39)
0·91 (0·75–1·11)
0·82 (0·62–1·09)
Self-monitoring Control Hazard ratio (random) Hazard ratio (95% CI)
0·1 0·2 0·5 1 2 5 10
0·1 0·2 0·5 1 2 5 10
0·1 0·2 0·5 1 2 5
Favours self-monitoring Favours control
10
A
B
C
Figure 4: Comparison by type of monitoring (self-monitoring compared with self-testing only)
Thrombosis (A), major haemorrhage (B), and death (C).
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Analysis of major outcomes in the very elderly 
(≥85 years, n=99) showed no signiﬁ cant adverse eﬀ ects 
of self-monitoring for all outcomes, and a reduction in 
mortality was seen (hazard ratio 0·44, 95% CI 0·20–0·98; 
p=0·044; I²=0); however, the number of participants in 
this analysis was small (n=75).
We postulated that type of control care in our pre-
speciﬁ ed subgroups might aﬀ ect the overall eﬀ ectiveness 
of self-monitoring. Yet, little diﬀ erence was seen in terms 
of anticoagulation clinic care versus primary care for 
thromboembolic events (ﬁ gure 3; χ² 2·18, p=0·34); major 
haemorrhage (χ² 1·01, p=0·60), and death outcomes 
(χ² 3·25, p=0·20).
A signiﬁ cant reduction in thromboembolic events was 
seen in men with a mechanical heart valve who were 
self-monitoring (ﬁ gure 5; p=0·002, I²=13·8), which was 
not signiﬁ cant in women (ﬁ gure 5; p=0·99; I²=5·8). 
However, the number of women was small (n=447 for 
Thrombosis
Sex
Male
Female
Age (years)
<65
≥65
Total
Major haemorrhage
Male
Female
Age (years)
<65
≥65
Total
Death
Male
Female
Age
<65
≥65
Total
Self-monitoring Control OE Variance Hazard ratio (random) Hazard ratio (95% CI)
28/853
8/211
22/745
14/376
36/1132
65/860
13/226
44/665
34/400
78/1111
56/852
8/232
24/701
40/395
64/1101
53/748
10/236
32/552
31/473
63/1040
77/743
14/249
36/499
54/484
91/1015
54/735
21/252
28/518
47/476
75/1002
–15·07
–0·02
–8·55
–6·94
–11·62
1·01
–0·36
–8·78
–3·53
–5·38
–6·57
–0·54
19·93
4·40
13·00
10·84
34·86
6·42
19·25
21·31
27·11
7·17
12·37
21·02
Interaction test
p=0·15
0·42 (0·24–0·72)
1·00 (0·39–2·53)
0·52 (0·30–0·89)
0·53 (0·29–0·96)
0·52 (0·35–0·77)
0·72 (0·51–1·00)
1·17 (0·54–2·54)
0·98 (0·63–1·53)
0·66 (0·43–1·01)
0·78 (0·58–1·06)
0·88 (0·60–1·28)
0·88 (0·19–4·00)
0·62 (0·27–1·43)
0·97 (0·64–1·49)
0·80 (0·42–1·52)
Thrombosis
Sex
Male
Female
Age (years)
<65
≥65
Total
Major haemorrhage
Male
Female
Age (years)
<65
≥65
Total
Death
Male
Female
Age (years)
<65
≥65
Total
65/1405
5/122
19/462
51/1060
70/1629
119/1462
7/186
37/477
89/1087
126/1676
129/1341
9/186
32/512
106/1030
138/1555
59/1382
10/129
19/425
50/1093
69/1623
107/1438
12/200
25/456
94/1120
119/1677
143/1322
13/200
31/470
125/1067
156/1549
1·52
–1·18
–0·85
1·34
2·57
–0·43
4·66
–2·24
–12·63
–1·28
–0·81
–13·04
30·95
3·45
9·46
24·90
56·30
3·85
15·37
44·84
67·23
5·28
15·71
56·62
p=0·490·58 (0·14–2·37)
0·71 (0·25–2·04)
0·91 (0·48–1·73)
0·89 (0·44–1·78)
0·67 (0·28–1·57)
1·05 (0·81–1·36)
0·89 (0·33–2·43)
1·35 (0·82–2·23)
0·95 (0·71–1·27)
1·04 (0·81–1·34)
0·83 (0·65–1·05)
0·94 (0·30–2·97)
0·59 (0·13–2·65)
0·76 (0·49–1·19)
0·72 (0·43–1·20)
p=0·97
p=0·25
p=0·21
p=0·14
p=0·16
p=0·71
p=0·76
p=0·23
p=0·91
p=0·53
B
A
0·1 0·2 0·5 1 2 5 10
0·1 0·2
Favours
self-monitoring
Favours
control
0·5 1 2 5 10
Figure 5: Major outcomes in mechanical valve and atrial ﬁ brillation by age and sex
Patients with mechanical valve by sex and age (<65 years and ≥65 years; A) and patients with atrial ﬁ brillation by sex and age (<65 years and ≥65 years; B). 
O–E=observed minus expected.
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thrombosis) and this interaction was not signiﬁ cant 
(χ² 2·04, p=0·15). Men with a mechanical valve who were 
self-monitoring also had a signiﬁ cant reduction in major 
haemorrhagic events (ﬁ gure 5; p=0·049; I²=0), whereas 
women did not (ﬁ gure 5; p=0·69; I²=0). However, the 
interaction test was not signiﬁ cant (χ² 1·31, p=0·25).
Participants younger than 65 years and those 65 years 
or older with a mechanical heart valve who were 
self-monitoring oral anticoagulation showed similar 
signiﬁ cant reductions with roughly a halving of 
thrombotic events (ﬁ gure 5). We saw no signiﬁ cant 
eﬀ ects or interaction in terms of major haemorrhage and 
death for other subgroups of participants with a 
mechanical valve. In participants with atrial ﬁ brillation, 
we saw no signiﬁ cant eﬀ ects across subgroups by sex or 
age, and no signiﬁ cant interactions (ﬁ gure 5).
One study17 provided data only at 90 days for the mean 
time in therapeutic range (table 3). The time in therapeutic 
range improved and SDs decreased over time. By 1 year, 
four trials18,20–22 showed improvements in the intervention 
group, whereas the three trials,19,23,24 which did not show 
improvement, all had smaller SDs in the intervention 
group. In the ﬁ rst 7 days participants with atrial ﬁ brillation 
and a mechanical heart valve who self-monitored oral 
anticoagulation spent signiﬁ cantly more time in thera-
peutic range than did those who did not self-monitor 
Country 7 days 30 days 90 days 6 months 1 year
Intervention Control Intervention Control Intervention Control Intervention Control Intervention Control
Cromheecke 
et al17
Holland ·· ·· ·· ·· 57·8 (14·5) 47·8 (18·6) ·· ·· ·· ··
Körtke et al18 Germany 49·2% (42·9) 56·9% (41·3) 71·2% (28·7) 55·7% (35·5) 78·2% (22·0) 59·6% (32·5) 80·9% (20·0) 60·6% (31·2) 83·0% (18·6) 61·7 (30·8 )
Menéndez-
Jándula et al
Spain 66·7% (37·4) 62·5% (44·7) 66·2% (26·7) 68·2% (36·2) 66·2% (18·6) 68·5% (27·2) 68·0% (16·0) 69·0% (22·3) 67·9% (14·0) 68·8 (20·0)
Fitzmaurice 
et al20
UK  66·6% (40·4) 53·2% (45·3) 69·7% (32·2) 63·9% (36·8) 70·7% (25·1) 63·6% (31·7) 71·0% (23·0) 63·4% (28·8) 71·7% (22·0) 63·8 (28·4)
Christensen21 
et al
Denmark 80·2% (24·3) 61·7% (44·1) 78·3% (24·6) 71·2% (33·7) 77·5% (20·6) 67·7% (30·9) 75·5% (18·9) 67·3% (24·5) 75·5% (18·9) 67·4 (24·2)
Siebenhofer23 
et al
Austria  43·6% (43·5 ) 52·9% (44·0) 51·0% (36·6) 61·5% (35·8) 53·6% (26·2) 63·3% (29·7) 57·4% (24·5) 65·0% (26·5) 61·3% (19·9) 64·5 (21·1)
Matchar et al22 USA 63·3% (21·7) 52·3% (25·1) 63·5% (16·0) 53·0% (20·3) 64·1% (14·6) 55·1% (19·9) 65·1% (14·1) 57·7% (19·9) 67·2% (14·0) 61·0 (20·1)
Kaatz  et al24 USA 59·7% (40·0) 61·1% (41·6) 56·6% (28·7) 66·9% (32·1) 62·9% (21·6) 70·0% (25·3) 64·7% (19·6) 71·6% (19·9) 65·9% (17·4) 70·8 (17·6)
Data are mean (SD).
Table 3: Percentage mean time in therapeutic range at 7 days to 1 year
Time in therapeutic range Number of tests
Mean diﬀ erence between self-monitoring 
and control group (95% CI)
Heterogeneity p value Mean diﬀ erence between self-monitoring 
and control group (95% CI)
Heterogeneity p value
7 days 12·25% (8·99 to 15·51) 0 <0·001 0·25 (0·10 to 0·39) 77% 0·001
30 days 6·13% (–0·09 to 12·35) 72% 0·05 2·28 (1·59 to 2·97) 94% <0·001
6 months 5·13% (–1·13 to 11·40) 79% 0·11 12·71 (9·33 to 16·10) 96% <0·001
1 year 2·71% (–6·10 to 11·51) 94% 0·55 24·22 (18·40 to 30·04) 93% <0·001 
Data % or % (95% CI).
Table 4: Mean diﬀ erence between self-monitoring and control group in time in therapeutic range and number of tests for participants with a 
mechanical valve
Time in therapeutic range Number of tests
Mean diﬀ erence between self-monitoring 
and control group (95% CI)
Heterogeneity p value Mean diﬀ erence between self-monitoring 
and control group (95% CI)
Heterogeneity p value
7 days 10·38% (8·56 to 12·20) 0% <0·001 0·01 (–0·25 to 0·28) 92% 0·91
30 days 3·16% (–4·07 to 10·39) 77% 0·39 1·78 (0·97 to 2·60) 97% <0·001 
6 months 4·40% (–0·86 to 9·67) 79% 0·10 12·03 (7·46 to 16·60) 99% <0·001 
1 year 5·13% (0·97 to 9·28) 57% 0·02 21·74 (13·11 to 30·37) 98% <0·001
Data % or % (95% CI).
Table 5: Mean diﬀ erence between self-monitoring and control group in time in therapeutic range and number of tests for participants with atrial ﬁ brillation
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(table 4, table 5), but over time the diﬀ erences between 
groups reduced. Self-monitoring also led to an increase 
in the number of tests undertaken. At 1 year, participants 
with a mechanical valve or atrial ﬁ brillation undertook 
more tests per year than did those receiving usual care 
(table 4, table 5). The substantial variation between 
studies was illustrated by the high heterogeneity.
Discussion
Our study used individual patient data for assessment of 
self-monitoring for oral anticoagulation. Overall, we 
observed a signiﬁ cant reduction in thromboembolic 
events in the self-monitoring group. However, we did 
not ﬁ nd any signiﬁ cant eﬀ ects for major haemorrhage 
or mortality.
Our ﬁ ndings accord with those of previous systematic 
reviews, in which patients who self-monitor or self-
manage could improve the quality of their oral-
anticoagulation therapy. However, despite the decrease 
in the number of thromboembolic events without 
concomitant increases in harms, we did not see the 
reduction in mortality shown in previous systematic 
reviews.4–6 The odds ratio in a meta-analysis by Bloomﬁ eld 
and colleagues39 was similar to our result for reduction in 
thromboembolic events (odds ratio 0·58, 95% CI 
0·45–0·75; p<0·001). However, the result for death was 
similar in eﬀ ect size, but the observed result diﬀ ered 
signiﬁ cantly (odds ratio 0·74, 95% CI 0·63–0·87; 
p<0·001). This eﬀ ect was highly hetero geneous (I²=51%), 
which was attributed to the largest study to date.22 Reasons 
given for this high heterogeneity were that this large 
study had substantially longer follow-up and higher 
quality of control in the usual care group than did other 
similar studies. The trend for reduction in mortality 
favoured self-monitoring, yet our previous estimate for a 
reliable and conclusive treatment eﬀ ect would require 
5150 participants in each study group.6 Potentially, 
unavailable data from the ten studies that we were unable 
to access, were suﬃ  cient to remove the signiﬁ cance of 
this result.
Additionally, our previous estimate that self-monitoring 
was feasible for only half of patients requiring anti-
coagulant therapy might underestimate the true num-
bers. In the largest trial,22 about 80% (2922 of 3643) of 
trained patients were competent in the use of self-
monitoring equipment. Yet, even this estimate is con-
founded by eligibility criteria: in several trials20,32 fewer 
than 50% of the potentially eligible patients were 
randomly assigned. Self-monitoring patients deemed not 
com petent had higher numbers of practice attempts and 
higher cuvette wastage, and were less able to eﬃ  ciently 
do a ﬁ ngerstick procedure.40 Factors associated with 
unsuccessful self-monitoring include refusal by patients, 
exclusion by their family practitioner, failure to pass 
training, old age, poor cognition, and poor manual 
dexterity.6,20,40 One trial excluded people unable to attend 
training,19 and in another trial20 of an unselected 
population, young patients were more likely to 
successfully self-monitor oral anticoagulatoin.
In Germany 20% (160 000) of patients on anticoagulation 
undertook self-management, com pared with only 1% of 
those in USA who did self-testing at home. Reasons for 
this diﬀ erence include reim bursement, motivation by 
the patient, and willingness of the physician to support 
self-monitoring.20 Limitations include the reluctance of 
individuals to participate, but also the direct costs to 
patients and the training required for eﬀ ective 
monitoring.
In patients younger than 55 years of age, two-thirds 
reduction in thromboembolic events translated into 
21 participants self-monitoring for 1 year to prevent one 
thromboembolic event. For patients with a mechanical 
heart valve, a 50% decrease in thromboembolic events 
meant that the number needed to undertake self-
monitoring to prevent one event was 55 after 1 year and 
24 over 5 years. By comparison, 63 patients are needed to 
prevent one heart attack with daily statin therapy over 
5 years.41,42
Patients who self-tested and adjusted their doses had 
signiﬁ cantly lower rates of thromboembolic events, which 
suggests that patients should be given the opportunity, 
and provided with training, to undertake self-management. 
However, self-management does not mean that patients 
are left to fend for themselves: for instance, in one trial 
participants had 24 h back-up available,37 and good quality 
control measures are needed. The type of control care did 
not aﬀ ect the overall eﬀ ectiveness of self-monitoring. This 
ﬁ nding is often contradictory to the evidence, which shows 
that patients from community practices have signiﬁ cantly 
worse anticoagulation control than do those from antico-
agulation clinics. However, the same systematic review 
highlighted that patients recruited to clinical trials tended 
to spend more time in the therapeutic range than did 
those in the community.43
For participants with atrial ﬁ brillation we reported no 
signiﬁ cant eﬀ ects across subgroups by sex or age, and no 
signiﬁ cant interactions. Participants with atrial ﬁ bril lation 
were older than those with a mechanical heart valve, and 
in this age group, rates of events tended to be low. In a 
previous trial of 973 elderly patients in the community on 
anticoagulation, thromboembolic events were 1·4% 
a year.44
Mean time in therapeutic range tended to be better in 
the self-monitoring groups. Importantly, even when the 
time in therapeutic range showed worse control, the SDs 
were less, which suggests lower variation and therefore 
more stable control of oral anticoagulation than in the 
control care group.45 Full analysis of this issue is beyond 
the scope of this report, but is an important issue in 
establishing optimum anticoagulation control.
We also reported a reduction in mortality in very elderly 
patients who self-monitored oral anticoagulation. This 
result, although potentially misleading owing to the 
small numbers and number of analyses, warrants further 
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investigation. The evidence already supports the use of 
anticoagulation for elderly patients unless contra-
indications apply or patients decide the beneﬁ ts are not 
worth the inconvenience of such treatment.44 Our review 
was restricted to adults, although increasing numbers of 
children receive warfarin. But self-monitoring could be a 
safe and eﬀ ective management strategy for children and 
clinical studies are recommended.46
Some limitations are worth noting. First, we could have 
missed a study, especially because of non-publication. 
The results diﬀ er for publication bias because of variation 
in the methods for calculating Begg’s and Egger’s tests. 
Yet, the results of both suggest a weak eﬀ ect of publication 
bias due to eﬀ ects of small studies. Second, we were 
unable to obtain data from ten studies, although this was 
a small proportion of the overall dataset, which reduced 
the overall sample size. However, we were able to receive 
data from the largest trial to date, which was recently 
published.22 Third, some heterogeneity in outcomes was 
obsereved. Diﬀ erences occurred in the populations (ie, 
the monitor and the intervention populations), which all 
add to the inherent variability. Fourth, only a small 
number of participants aged over 85 years were included, 
and further research in this age group is needed. Finally, 
we do not know why fewer women than men were 
included and whether this is because women are reluctant 
to participate in self-monitoring or the overall recruitment 
strategies target men. One reason could be that in the 
largest study,22 which comprised nearly half of the data, 
only 1·7% of the included participants were women. 
Furthermore, the study was done in a Veterans Aﬀ airs 
population, which mainly includes men.
Adoption of self-monitoring will depend on ﬁ ndings 
from economic analyses, which in the past have produced 
conﬂ icting results. In the UK, a review concluded “in 
general, patient self-management is unlikely to be more 
cost-eﬀ ective than the current specialised anticoagulation 
clinics,”47 whereas a Canadian study suggested: “self-
management is a cost-eﬀ ective strategy for patients 
receiving long-term oral anticoagulation therapy for atrial 
ﬁ brillation or for a mechanical heart valve”.48
We believe the results of our review will lead to a 
systematic change in practice, in terms of the signiﬁ cant 
reduction in thromboembolic events in patients with a 
mechanical heart valve requiring long-term antico-
agulation. Such patients should be oﬀ ered the option to 
self-manage their disease with suitable health-care 
support as back-up. Additionally, several reviews and our 
study show that self-monitoring and self-management is 
a safe option for suitable patients.5,6,49
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